Microglial Activation and Inflammation as a Factor in the Pathogenesis of Progressive Supranuclear Palsy (PSP)

Progressive supranuclear palsy (PSP) is a neurodegenerative disease based on four-repeat tauopathy pathology. Currently, this entity is not fully recognized in the context of pathogenesis or clinical examination. This review evaluates the association between neuroinflammation and microglial activati...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in neuroscience Vol. 14; p. 893
Main Authors Alster, Piotr, Madetko, Natalia, Koziorowski, Dariusz, Friedman, Andrzej
Format Journal Article
LanguageEnglish
Published Lausanne Frontiers Research Foundation 02.09.2020
Frontiers Media S.A
Subjects
Brain research
Chronic traumatic encephalopathy
Cognitive ability
Coronaviruses
COVID-19
Cytokines
Genetic analysis
Hypotheses
Inflammation
Medical research
microglia
Nervous system
Neurodegeneration
Neurodegenerative diseases
Neuroimaging
neuroinflammation
Neuroscience
Paralysis
Parkinson's disease
Pathogenesis
Pathology
Pathophysiology
progressive supranucelar palsy
Progressive supranuclear palsy
PSP
Severe acute respiratory syndrome coronavirus 2
Tau protein
Tumor necrosis factor-TNF
Online AccessGet full text
ISSN1662-453X
1662-4548
1662-453X
DOI10.3389/fnins.2020.00893

Cover

More Information
Summary:Progressive supranuclear palsy (PSP) is a neurodegenerative disease based on four-repeat tauopathy pathology. Currently, this entity is not fully recognized in the context of pathogenesis or clinical examination. This review evaluates the association between neuroinflammation and microglial activation with the induction of pathological cascades that result in tauopathy pathology and the clinical manifestation of PSP. Multidimensional analysis was performed by evaluating genetic, biochemical, and neuroimaging biomarkers to determine whether neurodegeneration as an effect of neuroinflammation or neuroinflammation is a consequence of neurodegeneration in PSP. To the best of our knowledge, this review is the first to investigate PSP in this context.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
Reviewed by: Maud Gratuze, Washington University in St. Louis, United States; Cecile Delarasse, Institut National de la Santé et de la Recherche Médicale (INSERM), France; Iain Hartnell, University of Southampton, United Kingdom
Edited by: David Blum, INSERM U1172 Centre de Recherche Jean Pierre Aubert, France
This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neuroscience
ISSN:1662-453X
1662-4548
1662-453X
DOI:10.3389/fnins.2020.00893